<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254928</url>
  </required_header>
  <id_info>
    <org_study_id>MANCOR</org_study_id>
    <nct_id>NCT02254928</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Versus Daily rFSH in the Controlled Ovarian Stimulation of Poor Responders</brief_title>
  <acronym>MANCOR</acronym>
  <official_title>Comparative Study Between the Use of Corifollitropin Alfa and Daily Recombinant FSH in the Controlled Ovarian Stimulation of Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVI Sevilla</source>
  <brief_summary>
    <textblock>
      A randomised, crossover, multicentre, national, clinical trial comparing the efficacy of
      corifollitropin alfa versus daily recombinant FSH and HMG in the controlled ovarian
      stimulation of women with a poor ovarian response undergoing IVF treatments. The main
      objective of this study is comparing the number of oocytes obtained after the follicle
      puncture when using each of these two stimulation protocols. Only poor responders according
      to the Bologna criteria will be recruited for this trial. All participants will undergo two
      stimulation cycles to obtain and accumulate oocytes by vitrification. One of the cycles will
      be done with the corifollitropin alfa protocol and the other with daily rFSH and HMG, the
      order of application of these protocols will be randomised (crossover clinical trial) in each
      patient.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of mature oocytes (metaphase II)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of mature oocytes (metaphase II) obtained after the follicle puncture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of oocytes</measure>
    <time_frame>1 year</time_frame>
    <description>Total number of oocytes obtained after the follicle puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms associated with the ovarian stimulation protocol</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will evaluate their symptoms using a questionnaire. They will score the intensity (from 1 to 10) of each of the following symptoms: pelvic pain, headache, mood swings, nausea, tiredness, breast pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient perception of the stimulation treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will evaluate how they have perceived the stimulation treatment using a questionnaire. They will score their comfort (from 1 to 10) with the following aspects of the treatment: treatment administration, number of injections and treatment length.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of the stimulation treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Days of stimulation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subcutaneous injections</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subcutaneous injections of gonadotropins (corifollitropin alfa, rFSH and HMG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <description>One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Elonva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced maternal age (≥40 years)

          -  A previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol)

          -  An abnormal ovarian reserve test (i.e. antral follicle count &lt;5-7 follicles or
             anti-mullerian hormone level &lt;0.5-1.1 ng/ml)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Seville</city>
        <zip>41006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor ovarian response</keyword>
  <keyword>controlled ovarian stimulation</keyword>
  <keyword>randomised clinical trial</keyword>
  <keyword>corifollitropin alfa</keyword>
  <keyword>recombinant follicle-stimulating hormone (rFSH)</keyword>
  <keyword>human menopausal gonadotropin (HMG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

